Skip to main navigation
Molecular Partners

> Top Menu

  • Partnering
  • Careers
  • Contact Us

> Investor Relations

  • About Us
  • DARPin Biology
  • The DARPin Platform
  • Pipeline
  • Investors
    • Overview
    • News & Events
      • News Releases
      • Events
      • Presentations
    • Scientific Documents
    • Stock Information
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Corporate Governance
      • Documents & Charters
      • Management Team & Board of Directors
      • Committee Composition
      • Major Shareholders
      • Management Transactions
    • ESG Overview
    • Ethics & Compliance
    • Financials & Filings
      • SEC Filings
      • Financial Reports
    • General Meeting
    • IR Resources
      • Email Alerts
      • Contact IR

> Top Menu

  • Partnering
  • Careers
  • Contact Us

> Investor Relations

  • About Us
  • DARPin Biology
  • The DARPin Platform
  • Pipeline
  • Investors
    • « Back
    • Overview
    • News & Events
      • « Back
      • News Releases
      • Events
      • Presentations
    • Scientific Documents
    • Stock Information
      • « Back
      • Stock Quote & Chart
      • Historic Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • Corporate Governance
      • « Back
      • Documents & Charters
      • Management Team & Board of Directors
      • Committee Composition
      • Major Shareholders
      • Management Transactions
    • ESG Overview
    • Ethics & Compliance
    • Financials & Filings
      • « Back
      • SEC Filings
      • Financial Reports
    • General Meeting
    • IR Resources
      • « Back
      • Email Alerts
      • Contact IR

Scientific

Scientific

  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
Event Publication Document
American Society for Hematology 1.4 MB
MP0533: A CD3 Engager DARPin Targeting CD33, CD123 & CD70 for the Treatment of AML and MDS
Society for the Immunotherapy of Cancer’s Annual meeting 1.8 MB
SITC 2022: Interim analysis of a phase 1 study with MP0317, a tumor targeting FAP dependent CD40 agonist DARPin, in patients with relapsed/refractory solid tumors
European Hematology Association - EHA2022 Congress 721.1 KB
MP0533, A New Multispecific DARPin CD3 Engager Targeting Three Tumor Associated Antigens Induces Specific T-cell Activation And AML Tumor Killing In Vivo
Antibody Engineering & Therapeutics EUROPE 4.6 MB
Ensovibep, a SARS-CoV-2 Multi-Variant Neutralizing DARPin Therapeutic
American Society for Microbiology: ASM MICROBE 1.3 MB
SARS-CoV-2 Omicron And Multi-variant Neutralization Activity Of Ensovibep: A DARPin Therapeutic Candidate For Treatment Of Covid-19 (a Novartis poster presentation)
GRC: Dissecting Evolution and Heterogeneity of Single Cancer Cells 2.5 MB
Characterization of Tumor Infiltrating Dendritic Cells at the Single Cell Level
ISAR-ICAR2022: 35TH International Conference on Antiviral Research 657.3 KB
SARS-CoV-2 Omicron and Pan-Variant Neutralization Activity of Ensovibep: a DARPin Therapeutic Candidate for Treatment of Covid-19

Investors

> Sidebar Menu

  • Overview
  • News & Events
    • News Releases
    • Events
    • Presentations
  • Scientific Documents
  • Stock Information
    • Stock Quote & Chart
    • Historical Price Lookup
    • Investment Calculator
    • Analyst Coverage
  • Corporate Governance
    • Documents & Charters
    • Management Team & Board of Directors
    • Committee Composition
    • Major Shareholders
    • Management Transactions
  • ESG Overview
  • Ethics & Compliance
  • Financials & Filings
    • SEC Filings
    • Financial Reports
  • General Meeting
  • IR Resources
    • Email Alerts
    • Contact IR

> Footer Menu

  • Cookie Notice
  • Privacy & Disclaimer
  • Contact Us

> Footer Social

© 2023 Molecular Partners.